<DOC>
	<DOCNO>NCT02323477</DOCNO>
	<brief_summary>The purpose phase 1/2 clinical trial evaluate efficacy safety allogeneic human umbilical cordstroma derive multipotent stem cell ( hUCS-MSCs ) myocardial infarction ( MI ) . All subject take bypass coronary surgery prior cell administration . This 2-year study comprise three independent group , first group ( n=20 ) take cell , second group take autologous BM-MNCs ( n=20 ) , third group ( n=39 ) receive allogeneic hUCS-MSCs . In transplantation cell administer approximately 10 peri-infarct area one time . The infarct zone determine MR , SPECT PET image . Only male subject 30-80 year age . The efficiency therapy evaluate accord parameter measure MR , SPECT , Echocardiography . All subject take measurement prior 6 , 12 , 18 24 month operation .</brief_summary>
	<brief_title>Human Umbilical Cord Stroma MSC Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Ischemic hearth disease experience CABG % 25 &lt; EF &lt; % 45 NYHA class IIIV patient hemodynamically stable Patient 's approval Acute cardiac decompensation Acute myocardial infarction Congenital heart disease Additional surgical heart disease coronary artery disease Malign arrhythmia All malignancy HbA1c level &gt; % 10 ( 86 mmol/mol ) type II diabetes mellitus Severe liver dysfunction Severe COPD Coagulopathy Immunosuppressive treatment Acute hepatitis , hepatitis B , C HIV infection Chronic liver renal failure Collagen tissue disease Stroke TB Hematological diseases Socially mentally disability</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cellular therapy</keyword>
	<keyword>chronic ischemic heart disease</keyword>
	<keyword>phase 1/2 clinical study</keyword>
	<keyword>human umbilical cord multipotent stem cell</keyword>
	<keyword>human umbilical cord mesenchymal stem cell</keyword>
	<keyword>ischemic heart disease</keyword>
	<keyword>bone marrow mononuclear cell</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
</DOC>